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Renal cell carcinoma (RCC) is the most prevalent cancer of
the kidney. In human RCC cells, we recently showed that
insulin-like growth factor I (IGF-I) has growth-promoting
effects regulated by IGF-binding protein 3 (IGFBP-3). In this
study, the analysis was expanded to include the interaction
between the IGF and transforming growth factor-b (TGF-b)
systems in the human RCC cells Caki-2 (from a primary
tumor) and SK-RC-52 (from a metastasis). Functional effects
such as cell proliferation, TGF-b receptor (TbR) signaling,
and IGFBP-3 levels were monitored after stimulation with
various concentrations of IGF-I, TGF-b, and IGFBP-3. In
addition, human RCC tissues as well as experimental
human RCC tumors were analyzed for cellular expression of
phosphorylated Smad2 by immunohistochemistry. TGF-b
regulated the endogenous IGFBP-3 levels in these RCC cells
as neutralizing anti-TGF-b(1–3) antibodies strongly reduced
the basal IGFBP-3 level. In addition, IGF-I increased the
IGFBP-3 levels five- to eightfold with TGF-b acting in synergy
to enhance the IGFBP-3 levels 12- to 17-fold. Neutralizing
TGF-b(1–3) activity circumvented the growth inhibitory
effects of IGFBP-3 seen in SK-RC-52, whereas it inhibited the
growth-promoting effects of IGFBP-3 in Caki-2. Moreover,
IGF-I interacted directly with TGF-b activation of the TbR
complex by enhancing phosphorylation and nuclear
translocation of Smad2. This study demonstrates a direct
interaction of the IGF and TGF-b systems in human renal
carcinoma cells. The observations that IGF-I enhances the
TGF-b signaling and that TGF-b promotes IGFBP-3 production
and thus influence the biological activity of IGF may be of
importance for future therapeutic options.
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Renal cell carcinoma (RCC) is a highly vascularized tumor
and the most frequent cancer of the kidney. Almost 50% of
the patients develop metastasis, and the prognoses for these
patients are relatively poor. The mechanisms responsible for
tumor growth and progression of RCC are unclear; however,
the von Hippel–Lindau (VHL) tumor suppressor gene is
mutated in most patients with sporadic clear-cell RCC,1
which leads to autocrine dysregulation of several functions
including vascular endothelial growth factor, transforming
growth factor-b (TGF-b), and insulin-like growth factor
(IGF) actions.2–4 Like several other forms of cancer, RCC can
exhibit insulin-like growth factor I (IGF-I)-dependent
growth through the type I IGF tyrosine kinase receptor.5–7
Retrospective studies suggest that type I IGF tyrosine kinase
receptor expression in the primary tumor is associated
with poor survival of patients with early-stage RCC8 and
high pretreatment IGF-I levels may limit the efficacy of
interleukin-2 immunotherapy in advanced cancer patients.9
In addition, increased gene expression and plasma levels of
IGF-binding protein 3 (IGFBP-3) and TGF-b1 are commonly
associated with RCC tumors.10,11
IGFBP-3 is the main carrier of IGFs in the circulation,
where this complex prolongs the half-life of the IGFs and
regulates their biological response.12 Accumulating evidence
suggests that the IGFBP-3 plays an important role in the
regulation of both cell growth and death, independently of its
interaction with the IGFs.13,14
TGF-b is a multifunctional cytokine that belongs to a
large family of structurally homologous dimeric proteins.
TGF-b exhibits a broad array of biological effects including
immunosuppression, regulation of extracellular matrix
formation, stimulation of angiogenesis, as well as growth
inhibitory or stimulatory effects depending on target
cell.15 The biological response to TGF-b involves a cascade
of interdependent events from the cell surface serine/
threonine kinase receptors to the nucleus. TGF-b binds the
constitutively active type II TGF-b receptor (TbRII), which
then phosphorylate the type I TGF-b receptor. Down-
stream signals are propagated by activated and phosphory-
lated Smad2 and Smad3, which associate with the common
mediator Smad4 and are translocated to the nucleus
where they participate in the regulation of transcription of
target genes.16
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In malignancies such as breast cancer, IGFBP-3 and TGF-b
can interact with each other’s signaling pathways and it has
been suggested that they may regulate each other’s cellular
effects. TGF-b1 increases the secretion of IGFBP-3 in a variety
of breast cancer cell lines.17,18 In turn, IGFBP-3 potentiates
the TGF-b effects by enhancing the phosphorylation of
Smad2 and Smad3. Moreover, inhibitory IGFBP-3 signaling
has been suggested to require an active TGF-b signaling
pathway and the presence of TGF-b and TbRII.19,20
In this study, the cross-talk between the TGF-b super-
family and IGF system in human RCC was investigated.
Furthermore, we examined the functional effects of TGF-b1
on IGFBP-3 production and cell growth modulation, as well
as the effects of IGF-I and IGFBP-3 induction of TbR
complex signaling by phosphorylation of Smad2.
RESULTS
Phosphorylated Smad2 in human RCC tissue indicates an
active TbR signaling
The TGF-b system has a role in the pathogenesis of several
human cancers, manifested in increased serum levels of TGF-
b1 and impaired or altered TbR signaling.10,15,21 To examine
if there are indications of active TGF-b signaling pathways in
human renal cancer, tissues from four clear cell, one papillary,
as well as four experimental xenograft tumors of Caki-2 cells
or one of SK-RC-52 cells were analyzed by immunohisto-
chemistry for the expression of TbRs and Smad proteins.
A strong immunoreactivity of phosphorylated Smad2
was observed in the majority of tumor cells, whereas an
intermediate staining was observed in vascular endothelial
cells from both human RCC tissue (Figure 1a) and xeno-
graft Caki-2 (Figure 1b) and SK-RC-52 tumors (Figure 1c).
Importantly, these cells displayed a significant nuclear
accumulation of pSmad2, indicating an ongoing signaling.
In sharp contrast, neither cytoplasmic nor nuclear pSmad2
was detected in the surrounding stromal cells in the
human RCC tissue (Figure 1a). Type I TGF-b receptor/
ALK-5 was expressed on tumor, stroma, and endothelial cell.
A homogeneous immunoreaction of TbRII was shown on the
tumor and endothelial cells, whereas stroma and suben-
dothelial cells showed a weaker reaction. A similar immuno-
staining was detected for Smad2, Smad3, and Smad4
signaling proteins (data not shown).
The immunoreactions appeared similar among the tumor
samples analyzed, and the xenograft RCC tumors showed a
similar immunostaining of all TbR signaling members as the
human tumor tissues. These results show the presence of all
members essential to form the TbR complex in human RCC.
Most importantly, the majority of the tumor cells, in contrast
to stromal cells, transduce an active TbR signaling monitored
as nuclear translocation of pSmad2.
Effects of TGF-b1 on growth control
TGF-b1 is known to mediate either inhibitory or stimulatory
effects on cell growth of various tumors. The growth-
modulating effects of TGF-b1 in the presence or absence of
IGF-I and IGFBP-3 were investigated in vitro. High
concentrations of exogenous TGF-b1 had a small stimulating
effect on Caki-2 cell growth in the absence of other growth
factors (Figure 2a). Treatment with constant concentrations
of IGF-I or a combination of IGF-I and IGFBP-3 strongly
enhanced the cell growth; however, addition of low doses of
TGF-b1 (1 ng/ml) inhibited the proliferative response to IGF-I
and to IGF-I with IGFBP-3 by 11 and 23%, respectively.
Further, increased TGF-b1 concentrations (10 ng/ml) almost
restored the proliferation rate to control levels. In contrast,
recombinant TGF-b1 inhibited the basal cell growth of
SK-RC-52 cells with a decrease in proliferation of 22% at
5 ng/ml as compared to control (Figure 2b). The suppressive
effect of TGF-b1 was further enhanced in the presence
of IGF-I or the combination of IGF-I and IGFBP-3, where
5 ng/ml TGF-b1 decreased the proliferative response to IGF-I
by 48% and to IGF-I with IGFBP-3 by 57% (Figure 2b). Thus,
TGF-b affects the proliferative activity differently in these
RCC cells. IGF-I and IGFBP-3 seem to sensitize the cells to
growth inhibitory effects of TGF-b1.
TGF-b1 treatment increases IGFBP-3 levels
In addition to TGF-b1, IGFBP-3 levels are often elevated in
RCC patients and may play a role in pathogenesis.11 To
investigate the effects of IGF-I and TGF-b1 on the regula-
tion of IGFBP-3 levels, serum-free conditioned medium
from treated Caki-2 and SK-RC-52 cells were collected
and analyzed for IGFBP-3 content (Table 1). Basal levels of
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Figure 1 | Cellular distribution of phosphorylated Smad2 in
human RCC tissue and xenograft RCC tumors. Clear-cell RCC
cryosections (8 mm) were immunostained for pSmad2 as described in
the Materials and Methods section. The expression is visualized in
brown by diaminobenzidineþ and cells counterstained by methyl
green. Tumor cells in (a) human clear-cell RCC tissue, (b) xenograft
Caki-2, and (c) xenograft SK-RC-52 tumors showed a positive nuclear
staining of pSmad2 as indicated by arrows. No immunoreactivity was
observed in the surrounding stromal cells (S) in the (a) human RCC
tissue. (a, c) Bar¼ 50mm or (b) 100 mm. The illustrations show one
representative tissue from each tumor type from experiments
repeated at least three times.
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IGFBP-3 were in the order of 1–1.5 ng/ml. TGF-b1 treatment
increased the IGFBP-3 protein level threefold in Caki-2 cells
and sevenfold in SK-RC-52 cells. In addition, the IGFBP-3
level was enhanced fivefold for Caki-2 and eightfold for
SK-RC-52 after IGF-I treatment (Pp0.001). Concomitant
treatment with IGF-I and TGF-b1 had a synergistic effect on
IGFBP-3 levels, which were increased 12-fold (Caki-2) or
17-fold (SK-RC-52) (Pp0.001). In contrast, neutralizing
TGF-b(1–3) strongly reduced the basal level of IGFBP-3
by 32% in Caki-2 and 60% in SK-RC-52 (Pp0.001).
These findings demonstrate the involvement of TGF-b in
the regulation of IGFBP-3 protein levels, resulting in tight
interaction of their respective functional cellular responses.
Effects of IGFBP-3 on cell growth after TGF-b(1–3)
neutralization
The involvement of autocrine TGF-b on the proliferative
responses to IGF and/or IGFBP-3 was investigated by adding
neutralizing TGF-b(1–3) monoclonal antibody (mAb) to the
cells under serum-free conditions. An excess of neutralizing
TGF-b(1–3) antibody dose dependently decreased the IGF-I-,
IGFBP-3-, or IGF-I/IGFBP-3-induced proliferation rate of
Caki-2, with a maximum inhibition of 30% at 20 mg/ml
with simultaneous treatment with IGFBP-3 or IGF-I/IGFBP-3
(Figure 3a). In contrast, neutralizing any endogenous TGF-b
activity in SK-RC-52 cells using the neutralizing TGF-b(1–3)
antibody dose dependently enhanced the basal proliferation,
with a maximum increase of 44% at 20 mg/ml as compared to
control (Figure 3b). However, the cell growth after neutraliz-
ing endogenous TGF-b(1–3) was not further affected by the
presence of exogenous IGF-I, IGFBP-3, or the two combined.
Thus, TGF-b displays disparate effects on the basal growth of
these RCC cells. These data suggest an effect of endogenously
produced TGF-b on the IGF-I- and IGFBP-3-mediated auto-
or paracrine cell growth of Caki-2 cells in vitro.
IGF-I induces Smad2 phosphorylation in Caki-2 cells
As a measurement of active TGF-b signaling, the induction
and phosphorylation pattern of Smad2 in Caki-2 or SK-RC-
52 cells by TGF-b, and the impact by IGF-I and IGFBP-3, was
analyzed in vitro using semiquantitative immunocytostain-
ing. For Caki-2, a very low basal level of pSmad2 was detected
in untreated control cells (Figure 4a). Treatment with
exogenous TGF-b1 only resulted in a weak induction of
Smad2 phosphorylation (Figure 4b). Interestingly, concomi-
tant treatment with IGF-I strongly enhanced this phosphory-
lation and a distinct nuclear localization was observed,
demonstrating full onset of TGF-b-regulated genes
(Figure 4e). Notably, the Smad2 phosphorylation after IGF-
I treatment was still strongly enhanced even in the absence of
exogenous TGF-b1 (Figure 4d) and after antibody neutrali-
zation of endogenous TGF-b(1–3) (Figure 4f), although the
pSmad2 levels were reduced compared to the combination
of IGF-I and TGF-b1 (Figure 4e) and were approximately
equal to IGF-I alone (Figure 4d). Furthermore, IGFBP-3
treatment enhanced the phosphorylation of Smad2. However,
concomitant incubation with IGF-I reduced the levels of
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Figure 2 | Differential effects of TGF-b on Caki-2 and SK-RC-52 cell
growth in vitro. Proliferation determined by 3H-thymidine uptake of
(a) Caki-2 and (b) SK-RC-52 cells cultured 48 h in SFM (white bars) or
in SFM containing IGF-I (32 ng/ml) (black bars) or IGF-I (32 ng/ml)
þ IGFBP-3 (250 ng/ml) (gray bars) and increasing concentrations of
TGF-b1. Graph represents the mean of three experiments each
repeated in triplicate.
Table 1 | IGF-I and TGF-b1 synergistically induce IGFBP-3 expression in RCC cells
IGFBP-3 (ng/ml)
Cell line Basal expression IGF-I stimulation TGF-b1 stimulation IGF-I+TGF-b1 stimulation TGF-b(1–3) neutralization
Caki-2 1.0170.11 5.1070.36 3.5170.37 11.8570.82 0.6970.08
SK-RC-52 1.4670.12 11.6771.19 10.4671.12 25.3571.55 0.5870.17
IGF-I, insulin-like growth factor I; IGFBP-3, IGF-binding protein 3; RCC, renal cell carcinoma; TGF-b1, transforming growth factor-b.
IGFBP-3 levels in 100 ml conditioned medium from RCC cells grown for 72 h in SFM in the presence or absence of IGF-I (32 ng/ml), TGF-b1 (5 ng/ml), or neutralizing anti-TGF-
b(1–3) Ab (20 mg/ml) were measured by ELISA assay as described under ‘Materials and Methods’. Results are shown as the means7s.e. of six replicate wells from one of three
independent experiments. The various treatments were statistically significant (Pp0.001) relative to basal IGFBP-3 expression.
a
0
2
4
6
8
10
12
SFM IGF-I IGFBP-3 IGF-I +
IGFBP-3
SFM IGF-I IGFBP-3 IGF-I +
IGFBP-3
Pr
ol
ife
ra
tio
n 
(x1
03
 
c.
p.
m
.)
Pr
ol
ife
ra
tio
n 
(x1
03
 
c.
p.
m
.)
b 10
0
2
4
6
8
Figure 3 | TGF-b neutralization counteracts IGFBP-3 cellular
effects. Proliferation determined by 3H-thymidine uptake of
(a) Caki-2 and (b) SK-RC-52 cells cultured 48 h in SFM, SFM containing
IGF-I (32 ng/ml), or IGF-I (32 ng/ml) in combination with IGFBP-3
(250 ng/ml) in the presence of neutralizing anti-TGF-b(1–3) mAb 0
mg/ml (white bars), 10 mg/ml (black bars), or 20 mg/ml (gray bars).
Graph represents the mean of three experiments each repeated in
triplicate.
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pSmad2. A similar reduction of IGFBP-3-induced pSmad2
was noted after endogenous TGF-b(1–3) neutralization (data
not shown). As for Caki-2, a very weak basal level of pSmad2
was detected in untreated SK-RC-52 cells. The staining
was mainly cytoplasmic and only few cells demonstrated
nuclear translocated pSmad2. Incubation with IGF-I alone
or in the combination with TGF-b1 did not affect the
Smad2 phosphorylation to a degree significantly different
from the basal level. As the staining intensity was very weak,
no conclusive results could be obtained for the activation of
Smad2 after TGF-b1 or IGF-I stimulation in SK-RC-52 (data
not shown). These results suggest that differential signaling
pathways are activated upon TGF-b treatment in these cells.
Furthermore, the results show potential signaling crosstalk
between the IGF and TGF-b systems in Caki-2 cells, where
IGF-I is able to enhance downstream TbR signaling pathways
through the induction of pSmad2.
DISCUSSION
TGF-b and IGFBP-3 levels are increased in RCC patients.10,11
However, their roles in disease progression are poorly
understood. We investigated the responsiveness to TGF-b
and interactions between the TbR and IGF receptor signaling
pathways in one primary tumor and one mediastinal
metastasis RCC cell line. The results demonstrate that these
signaling pathways indeed are coupled in these RCC cells.
TGF-b influences the levels of IGFBP-3, thus regulating its
intrinsic effects as well as the effects of IGFs. Moreover, IGF-I
and IGFBP-3 influence the TGF-b signaling by enhancing
both phosphorylation and nuclear translocation of Smad2.
TGF-b-induced growth inhibition of the SK-RC-52
metastasis cell line was accompanied by a concomitant
increase in endogenous IGFBP-3 levels. In these cells, IGFBP-
3 acts as a negative regulator and suppress cellular growth.6
The sensitivity to TGF-b-induced growth inhibition was
further enhanced by co-treatment with exogenous IGFBP-3
and TGF-b. Neutralization of TGF-b reduced the IGFBP-3
levels, which led to enhanced basal proliferation and partially
rescued SK-RC-52 cells from TGF-b and IGFBP-3 growth-
inhibitory effects. These results are consistent with previously
described breast cancer systems, where TGF-b-induced
growth inhibition at least partly occurs through an increased
production of IGFBP-317 and where IGFBP-3 can activate the
TGF-b signaling pathway by enhancing the phosphorylation
of Smad2 and Smad3, thus increasing the sensitivity to
TGF-b growth-modulating effects.19,20
TGF-b also increased IGFBP-3 levels in Caki-2 cells.
However, in sharp contrast to SK-RC-52, IGFBP-3 enhances
proliferation in this primary tumor cell.6 In line with
this, TGF-b treatment slightly stimulated cell growth,
whereas neutralization of TGF-b reduced the basal IGFBP-3
production and subsequently inhibited the prolifera-
tion. Thus, our results suggest that a role of TGF-b in RCC
cells is to influence the production and modulate the effects
of IGFBP-3.
Whereas TGF-b1-mediated growth inhibition of Caki-2
was only revealed in the presence of exogenous IGF-I, TGF-
b1 suppressed the basal growth of SK-RC-52, although the
growth inhibitory properties of TGF-b1 appeared to be more
pronounced in the presence of IGF-I. Thus, one alternative
way to interpret our data would be that TGF-b inhibition
occurs via inhibition of IGF-mediated growth and that the
different responses to TGF-b actions on the basal growth in
these cells may be a result of differences in their autocrine
IGF production. However, Caki-2, in which basal growth was
not suppressed by TGF-b1, produces low levels of IGF-II,
whereas no autocrine IGFs have been detected in the highly
TGF-b-responsive SK-RC-52.6 Thus, the observation that
TGF-b inhibition was enhanced in the presence of exogenous
IGF-I suggests that IGF-I sensitizes the cells to the growth
inhibitory properties of TGF-b.
TGF-b comprises both tumor suppressor and tumor
promoter functions, which are likely to be mediated by
differences in the activation of various downstream TbR
signaling pathways. However, it remains unclear during
which stage of tumor progression and through which
molecular mechanisms this pleiotrophic cytokine switches
its role from tumor suppressor to tumor promoter.22 A loss
of function or expression of the TbRII is observed in several
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Figure 4 | Enhanced induction and nuclear translocation of
phosphorylated Smad2 in Caki-2 cells by IGF-I stimulation. Caki-2
cells treated 15 min in (a–c) SFM or (d–f) SFM in the presence of IGF-I
32 ng/ml, (b, e) TGF-b1 5 ng/ml or (c, f) neutralizing anti-TGF-b(1-3)
mAb 20 mg/ml were immunostained for phosphorylated Smad2
(0.2mg/ml) and shown at original magnification  20. The expression
is visualized in brown by diaminobenzidine and cells counterstained
by methyl green. Green arrows indicate a positive nuclear staining
for pSmad2, whereas red arrows show negative staining. One
representative experiment out of two.
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tumors, including metastatic RCCs.21 The functional loss of
TGF-b responsiveness and thus loss of TGF-b-mediated
growth suppression has been shown to be associated with an
increased risk of transformation.15 Primary tumors may
reduce or alter their response to TGF-b in order to facilitate
invasiveness and metastatic potential.15,22 Furthermore, when
the metastasis reaches its secondary site, it may again adopt a
more primary tumor-like phenotype from a TGF-b perspec-
tive. Exogenous TGF-b1 only moderately affected the growth
properties of Caki-2, which may be owing to reduced or
altered sensitivity to TGF-b signaling. This was further
supported at the receptor signaling level where the basal
pSmad2 level was very low, and exogenous TGF-b1 only
marginally induced phosphorylation and nuclear trans-
location of Smad2, a hallmark of active TGF-b signaling.
Intrinsic activities of IGFBP-3 was previously described
to include signaling through the Smad pathway, where
IGFBP-3-stimulated phosphorylation of Smad2 and
Smad3 in T47D-RII and MCF-7 breast cancer cells.20 We
also confirmed that exogenous IGFBP-3 increased the
phosphorylation as well as nuclear translocation of Smad2
in Caki-2 cells. However, simultaneous incubation with
exogenous IGF-I reduced the levels of pSmad2. This might be
owing to complex formation of IGF-I:IGFBP-3, limiting free
IGFBP-3 to exert its biological actions and induce signaling.
Interestingly, IGF-I alone or in combination with TGF-b1
enhanced both the phosphorylation and distinct transloca-
tion to the nucleus of pSmad2, indicating active receptor
signaling. This enhanced phosphorylation occurs after 10 min
of IGF-I stimulation, which renders it unlikely to be owing to
an increased IGFBP-3 production. Our current findings are
consistent with a recent publication where treatment of
prostatic epithelial cells with TGF-b1 and LR3-IGF-I (IGF-I
analog with reduced affinity for most IGFBPs) increased the
pSmad2 levels over the levels induced by TGF-b alone.23
Interestingly, although SK-RC-52 cells are highly responsive to
TGF-b1-mediated growth inhibition, the basal levels of
phosphorylated Smad2 were low and mainly cytoplasmic.
Within the limits of the assay, further treatment with
exogenous TGF-b1 or IGF-I did not significantly alter the
phosphorylation or nuclear translocation of Smad2 as
compared with untreated cells. This indicates that other
signaling pathways may be mediating the growth inhibitory
effects of TGF-b1 on in vitro cultured SK-RC-52 cells. Thus, the
different responses to TGF-b actions noted in Caki-2 and SK-
RC-52 RCC cells are likely to be a consequence of differences in
the activation of their downstream TbR signaling pathways.
Our results indicate an alternative way of crosstalk
between the IGF tyrosine kinase and TGF-b serine/threonine
signaling pathways, in which IGF-I influences phosphoryla-
tion of a downstream signaling protein belonging to the TbR
signaling system. In line with this, in the physiological
situation where both IGF-I and TGF-b are present, the
xenograft Caki-2 tumors as well as the human RCC tissues
showed a strong nuclear accumulation of pSmad2. Caki-2
expresses all members required to transduce TGF-b signaling:
ALK-5, TbRII, Smad2, Smad3, and Smad4 at a protein level
(data not shown). Thus, it is tempting to speculate that these
cells concomitantly express high levels of the general TbR
inhibitory Smad7, rendering these cells insensitive to TGF-b
treatment in vitro. IGF-I receptor signaling may interfere with
Smad7 binding to ALK-5 and thus making the Smad2
phosphorylation site on the TbR available. Further investiga-
tions are required to establish the molecular mechanisms by
which IGF-I interacts with the TGF-b signaling system.
Our results demonstrate ways of crosstalk between the IGF
and TGF-b systems in human RCC cells both at receptor
signaling as well as protein expression levels. We have
demonstrated that TGF-b is likely to regulate IGFBP-3
secretion and to transduce some of its cellular effects in these
RCC cells. Moreover, IGF-I enhances the phosphorylation of
Smad2 in primary Caki-2 cells. This enhanced knowledge
around the regulation and functional roles of growth fac-
tors in RCC, important during various stages in tumor
progression, may be of importance for future therapeutic
approaches.
MATERIALS AND METHODS
Reagents
Recombinant human IGF-I was from Pharmacia (Stockholm,
Sweden). Recombinant human IGFBP-3, TGF-b1, and neutralizing
anti-TGF-b(1–3) mAb were from R&D Systems (Abingdon,
Oxon, UK). Horseradish peroxidase-linked F(ab0)2 donkey-anti-
rabbit immunoglobulin was from Amersham Biosciences (Uppsala,
Sweden). The anti-TbRII and anti-ALK-5 were from Santa Cruz
Biotechnology Inc. (Santa Cruz, CA, USA). The affinity-purified
rabbit polycolonal Ab anti-pSmad2, anti-Smad2, anti-Smad3,
and anti-Smad4, as described previously,24,25 were kind gifts from
Dr P ten Dijke (Leiden, The Netherlands).
Animals and in vivo xenograft tumor model
Female severe-combined immunodeficient C.B-17 mice were bred
in-house and were routinely used at the age of 8–12 weeks. Caki-2 or
SK-RC-52 tumor cells (15 106 cells/ml) in 0.2 ml phosphate-
buffered saline (PBS) with 1% syngenic mouse serum were
inoculated intraperitoneally of severe-combined immunodeficient
mice. Mice were killed 45 days after tumor inoculation, tumors
resected, momentarily frozen, and kept at 701C until further use.
Cell lines
The human clear-cell RCC cell line Caki-2 was purchased from
American Type Culture Collection (Manassas, VA, USA). The
human clear-cell RCC cell line SK-RC-52 was a gift from Dr SO
Warnaar (Centocor, Leiden, The Netherlands). The cell lines were
maintained in R10 media (Roswell’s Park Memorial Institute media
1640 (BioWhittaker, Verviers, Belgium) supplemented with 10%
fetal bovine serum (Biotech Line AS, Lynge, Denmark) and 0.1 mg/
ml gentamicin (BioWhittaker, Verviers, Belgium)) in a humidified
5% CO2 atmosphere at 371C. All experiments were carried out in
serum-free Roswell’s Park Memorial Institute media 1640 with
0.1 mg/ml gentamicin (SFM).
Immunohistochemistry
Human biopsies (provided by Department of Surgery, Lund
University Hospital, Sweden) from RCC (histologically classified
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as four clear cell and one papillary carcinoma) as well as
experimental xenograft RCC tumors (four Caki-2 and one SK-RC-
52) were dissected and cryopreserved at 701C until used. Standard
immunohistochemical protocol was used with minor modifications.
Briefly, 8-mm-thick sections were fixed in 2% paraformaldehyde
(Sigma, Steinheim, Germany) in PBS (BioWhittaker, Verviers,
Belgium) for 30 min at room temperature. Endogenous peroxidase
activity was quenched for 10 min in darkness by 1% H2O2 (Merck,
Darmstadt, Germany) in PBS at room temperature. After blocking
with avidin/biotin (Vector SP2001, Burlingame, CA, USA) in the
presence of 5% normal donkey serum (Santa Cruz Biotechnology
Inc., Santa Cruz, CA, USA) for 40 and 20 min, respectively, at
room temperature, sections were incubated with 0.1mg/ml
anti-pSmad2, alternatively 0.3 mg/ml anti-ALK-5, anti-Smad2, anti-
Smad3, anti-Smad4, or 4 mg/ml anti-TbRII in Earle’s balanced
salt solution-Sap buffer (Earle’s balanced salt solution (Life
Technologies, Parsley, Scotland) with 0.01 M N-2-hydroxyethylpiper-
azine-N0-2-ethanesulfonic acid (BioWhittaker, Verviers, Belgium)
and 0.1% Saponin (Riedel-de Hae¨n, Seelze, Germany, pH 7.6) at 41C
overnight. Following washing, a 1:50 dilution of the horseradish
peroxidase-linked donkey-anti-rabbit immunoglobulin in Earle’s
balanced salt solution-Sap, supplemented with 2% normal donkey
serum, was added for 1 h at room temperature. The slides were
developed for 5 min in diaminobenzidine (DABþPlus) (Sigma,
Steinheim, Germany) and counterstained with methylgreen (Sigma,
Steinheim, Germany).
Cell proliferation assay
Cells were cultured (20 103 cells/well Caki-2 or 15 103 cells/well
SK-RC-52) in SFM in 96-well plates (Nunc, Roskilde, Denmark) in
the presence or absence of IGF-I (32 ng/ml) and/or IGFBP-3
(250 ng/ml) and various concentrations of TGF-b1 (0–10 ng/ml) or
neutralizing anti-TGF-b(1–3) mAb (0–20mg/ml). Following incuba-
tion for 48 h, cells were pulsed with 3H-thymidine (NEN, Boston,
MA, USA) (0.5 mCi/well) for 4 h at 371C as a measurement of DNA
synthesis and analyzed on a liquid scintillation b-counter (LKB
WALLAC, Perkin-Elmer Life Sciences, Zaventem, Belgium).
IGFBP-3 enzyme-linked immunosorbent assay
Cells were cultured (20 103 cells/well Caki-2 or 15 103 cells/well
SK-RC-52) in 200 ml SFM in the presence or absence of IGF-I (32 ng/
ml), TGF-b1 (5 ng/ml), IGF-I (32 ng/ml) in combination with
TGF-b1 (5 ng/ml), or neutralizing anti-TGF-b(1–3) Ab (20mg/ml)
in 96-well plates (Nunc, Roskilde, Denmark). Following incubation
for 72 h, the conditioned media were collected and assayed for
IGFBP-3, using IGFBP-3 DuoSet ELISA Development System (R&D
Systems, Abingdon, Oxon, UK), according to the manufacturer’s
instructions.
Immunocytochemistry
Cells were cultured (20 103 cells/well) for 48 h in R10 in eight-well
chamber slides (Lab-Tek II Chamber Slide System, Nunc). Cells
were then washed 2 with pre-heated SFM and subsequently
grown for 18 h in SFM with or without the presence of a
neutralizing anti-TGF-b(1–3) mAb (20 mg/ml). Cells were then
treated for 10 min with TGF-b1 (5 ng/ml) or 30 min with IGFBP-3
(500 ng/ml), with or without concomitant IGF-I (32 ng/ml).
Cells were subsequently washed 2 in ice-cold PBS, fixed in 2%
paraformaldehyde for 20 min at 41C, and washed 2 in ice-cold
PBS followed by immunohistochemical staining for pSmad2, as
described in the immunohistochemical section, with the modifica-
tion that cells were stained with primary and secondary Ab for
30 min at 41C.
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